# Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients

Study · id `cardio:ct-nct01448174` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01448174](<https://clinicaltrials.gov/study/NCT01448174>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01448174

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 310 participants.

## Technical summary

Registry record NCT01448174. Randomized; double masking; primary purpose basic science. Start 2011-10 (registry gives no type); primary completion 2014-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose basic science
- Phase: Phase 4
- Enrolled: 310 participants (enrolled count; ClinicalTrials.gov record NCT01448174, source copy `cardio:ctgov-nct01448174-2014-10-07`, retrieved 2026-10-26)
- Start date: 2011-10 (registry gives no type) (ClinicalTrials.gov record NCT01448174, source copy `cardio:ctgov-nct01448174-2014-10-07`, retrieved 2026-10-26)
- Primary completion: 2014-10 (actual) (ClinicalTrials.gov record NCT01448174, source copy `cardio:ctgov-nct01448174-2014-10-07`, retrieved 2026-10-26)
- Completion: 2014-10 (actual) (ClinicalTrials.gov record NCT01448174, source copy `cardio:ctgov-nct01448174-2014-10-07`, retrieved 2026-10-26)
- Countries: Poland (ClinicalTrials.gov record NCT01448174, source copy `cardio:ctgov-nct01448174-2014-10-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01448174-2014-10-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients
- Condition: Renal Failure Chronic Requiring Hemodialysis
- Condition: Metabolic Syndrome
- Condition: Diabetes Mellitus Type 2
- Condition: Hyperlipidemia
- Intervention (Drug): Atorvastatin
- Lead sponsor: Poznan University of Medical Sciences
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Metabolic syndrome (`cardio:metabolic-syndrome`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)
- Registry lists this organization as the lead sponsor: Poznan University of Medical Sciences (`cardio:org-poznan-university-of-medical-sciences`)

## Provenance

Content hash: a1db61aac8be51bec6b5791b0fc3e1bb7735d0d9256e1a60feccc9337e1ad32d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
